Dublin, Feb. 14, 2019 (GLOBE NEWSWIRE) -- The "Fabry Disease - Market Insights, Epidemiology and Market Forecast-2028" report has been added to ResearchAndMarkets.com's offering. The global market of Fabry Disease was estimated to be USD 1,211.3 million in 2018
Fabry Disease - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Fabry Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Fabry Disease from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Fabry Disease - Disease Understanding and Treatment Algorithm Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and caused by mutations in the GLA gene located in chromosome Xq22.1 and which encodes the alpha-galactosidase A (AGA) enzyme. It is a multi-systemic and a life-threatening condition which is one of the most common lysosomal storage disease after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleo-vestibular and cerebrovascular manifestations. Fabry Disease Epidemiology The Fabry Disease epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report is segmented by diagnosed prevalent population, gender-specific diagnosed prevalent population and phenotype-specific diagnosed prevalent population of Fabry Disease. The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight. According to this research, the prevalent population of Fabry Disease was estimated to be 16,800 [7MM] in 2018. United States accounts for the highest Fabry Disease cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Fabry Disease, followed by France. Fabry Disease Drug Chapters This segment of the Fabry Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Currently, the effective management of Fabry disease requires a multidisciplinary approach. Comprehensive therapy includes intravenously administered enzyme replacement therapy (ERT) or Oral Chaperone Therapy, conventional medical treatment, and adjunct therapies, and may include lifestyle modifications and prophylactic medications. Fabrazyme (Sanofi-Genzyme); Galafold (Amicus Therapeutics) and Replagal (Shire) are the approved therapies for the treatment of Fabry disease.
All these therapies are available in Europe and Japan however Replagal is withdrawn from the market in the US by the Shire in 2012. Galafold (migalastat) is a first-in-class chaperone therapy approved in the European Union as a monotherapy for Fabry disease in patients with amenable mutations. It got approved in May 2016 in Europe being developed by Amicus Therapeutics. Detailed chapters for all of these drugs have been covered in the report. Fabry Disease Market Outlook The Fabry Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. The dynamics of Fabry Disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Several companies are working robustly on many new therapies in Europe with novel mechanism of action; including Lucerastat (Idorsia Pharmaceuticals); Pegunigalsidase alfa (Protalix Biotherapeutics); Venglustat (Sanofi Genzyme) and AVR-RD-01 (Avrobio). The United States accounts for the largest market size of Fabry Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan Fabry Disease Drugs Uptake To counter current unmet needs of the market and to provide better treatment options for Fabry Disease, several companies are working robustly on developing new therapies with novel mechanism of action; including Lucerastat (Idorsia Pharmaceuticals); Pegunigalsidase alfa (Protalix Biotherapeutics); Venglustat (Sanofi Genzyme) and AVR-RD-01 (Avrobio) which are expected to enter Fabry Disease market by 2028. Lucerastat is a small molecule called an iminosugar, developed by Idorsia Pharmaceuticals for the treatment of Fabry Disease. It funtions as a substrate reduction therapy. The company is currently leading a pivotal Phase III study, which is being designed to assess the effects of lucerastat on neuropathic pain and gastrointestinal symptoms, as well as safety and tolerability, in patients with Fabry disease. Pegunigalsidase alfa (PRX-102) is a novel, PEGylated, chemically modified, a-galactosidase A enzyme replacement therapy developed by Protalix BioTherapeutics. It is currently in Phase III stage of development for the treatment of Fabry Disease.
Key Topics Covered: 1 Key Insights 2 Fabry Disease Market Overview at a Glance 2.1 Market Share (%) Distribution of Fabry Disease in 2017 2.2 Market Share (%) Distribution of Fabry Disease in 2028 3 Disease Background and Overview 3.1 Introduction 3.2 Classification 3.3 Signs and Symptoms 3.4 Etiology 3.5 Inheritance Pattern 3.6 Genetics 3.7 Pathogenesis 3.8 Molecular Basis 3.9 Diagnosis 3.10 European Fabry Working Group (EFWG): Diagnostic criteria 3.11 Challenges in Diagnosis 3.12 Diagnosis Algorithm for Fabry Disease 4 Epidemiology and Patient Population 4.1 Key Findings 5 7MM Total Prevalent Patient Population of Fabry Disease 6 Country Wise-Epidemiology of Fabry Disease 6.1 United States 6.2 EU5 6.3 Germany 6.4 France 6.5 Italy 6.6 Spain 6.7 United Kingdom 6.8 Japan 7 Treatment and Management of Fabry Disease 7.1 Guidelines for management of Fabry Disease 7.2 Croatian Society: Recommendation for the treatment of Fabry Disease 7.3 Treatment Practices 8 Treatment Algorithm 9 Unmet Needs 10 Marketed Drugs 10.1 Galafold: Amicus Therapeutics 10.2 Replagal: Shire 10.3 Fabrazyme: Genzyme 11 Emerging Therapies 11.1 Key cross competition- Emerging Therapies 11.2 Lucerastat: Idorsia Pharmaceuticals 11.3 Pegunigalsidase alfa: Protalix Biotherapeutics 11.4 AVR-RD-01: Avrobio 11.5 Venglustat: Sanofi Genzyme 12 Fabry Disease: 7 Major Market Analysis 12.1 Key Findings 12.2 Market Size of Fabry Disease in 7MM 13 Market Outlook by Country 14 The United States: Market Outlook 15 EU-5 Countries: Market Outlook 16 Market Drivers 17 Market Barriers 18 Appendix Companies Mentioned
- Amicus Therapeutics
- Shire
- Genzyme
- Idorsia Pharmaceuticals
- Protalix Biotherapeutics
- Avrobio
- Sanofi Genzyme
For more information about this report visit https://www.researchandmarkets.com/research/8...fabry?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Endocrine and Metabolic Disorders Drugs
